ACTR10

Across TCGA pan-cancer cohorts, ACTR10 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTR10 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACTR10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACTR10 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where ACTR10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.338	0.893	.002	56	view →
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	40	view →
HNSC	OS	Median	IV	0.912	0.753	.013	9	view →
PDAC	DFS	Median	III,IV	0.503	0.231	.004	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTR10–LUAD (OS)

Open the LUAD breakdown →